Search Results for "Sunitinib"

04:45 EST 23rd February 2017 | BioPortfolio

Matching Channels


Matching News

Adjuvant sunitinib for renal cell carcinoma

Dr Ravaud speaks with ecancertv at ESMO 2016 about results from a one-year trial of sunitinib vs placebo for post-nephrectomy high-risk renal cancer patients. This phase III trial found a longer di...

Sunitinib Potential New Option for Adjuvant Treatment in RCC

Patients with renal cell carcinoma at high risk for recurrence had prolonged disease-free survival when treated with sunitinib compared with placebo.

BRIEF-Exelixis announces positive results from phase 2 CABOSUN trial of Cabozantinib vs Sunitinib

* Cabozantinib met primary endpoint of improving progression-free survival as compared to Sunitinib

Early Intervention Important for Sunitinib-Related Hypertension in RCC

Patients with metastatic renal cell carcinoma treated with sunitinib often experience treatment-related hypertension and require rigorous blood pressure control.

Sunitinib Shows Promise as Adjuvant Therapy in RCC

Patients with renal cancer and a high risk for recurrence after nephrectomy may benefit from adjuvant sunitinib, which showed a disease-free survival benefit in a phase 3 trial. Medscape Medical New...

Pfizer's drug improves survival in kidney cancer study

Pfizer has unveiled results from the Phase 3 S-TRAC clinical trial (Sunitinib Trial as Adjuvant Treatment of Renal Cancer) investigating SUTENT (sunitinib) as adjuvant therapy.

First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT® (sunitinib) Extended Disease Free Survival After Surgical Removal

Monday, October 10th 2016 at 6:15am UTC Late-breaking data to be presented at the ESMO 2016 Congress and Published in The New England Journal of Medicine NEW YORK–(BUSINESS WIRE)– Pfizer I...

Sunitinib Breaks Feasible for Treatment-Naive Metastatic RCC

Breaks from active sunitinib treatment for patients with treatment-naive metastatic renal cell carcinoma may be possible without effecting clinical efficacy.

Matching PubMed Articles

Sunitinib uptake inhibits platelet function in cancer patients.

Sunitinib is an oral tyrosine kinase inhibitor used for cancer treatment. Patients treated with sunitinib are at higher bleeding risk. As tyrosine kinases are essential for platelet signalling, the ef...

The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma.

Molecular targeted therapy is a standard treatment for patients with advanced renal cell carcinoma (RCC). Sunitinib is one of the most common molecular-targeted drugs for metastatic RCC. Molecular mec...

Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.

Sunitinib is an orally delivered tyrosine kinase inhibitor that exhibits antiangiogenic effects. FDA has approved sunitinib for the treatment of metastatic renal cell carcinoma. However, its efficacy ...

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.

The most efficient sequence of targeted agents for metastatic renal cell carcinoma patients has yet to be identified. Whether the sequence of sorafenib and sunitinib really matters is controversial an...

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.

Sunitinib is a protein tyrosine kinase (PTK) inhibitor that has immune-modulating properties. In this context, peripheral blood mononuclear cells (PBMC), mainly constituted by lymphocytes, could be a ...

Search Whole site using Google

Quick Search
Advertisement Advertisement